Answers are grounded in this paper and cite their sources.
Iron overload remains a major cause of morbidity and mortality in patients with thalassemia, particularly due to cardiac siderosis. Although iron chelation therapy (ICT) is the cornerstone of management, it may be insufficient to prevent progressive iron accumulation. Calcium channel blockers (CCBs), such as amlodipine, have been proposed as adjunctive therapy to reduce myocardial iron uptake. We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy of amlodipine combined with standard ICT in thalassemia patients. This study followed PRISMA guidelines and was registered in PROSPERO. A comprehensive search of Embase, PubMed, Medline, Scopus, and Web of Science was conducted up to August 2025. We included RCTs evaluating amlodipine plus ICT versus ICT plus placebo or non-CCB supplements in patients with thalassemia. Primary outcomes were serum ferritin, liver iron concentration (LIC), myocardial iron concentration (MIC), myocardial T2*, and left ventricular ejection fraction (LVEF). Pooled analyses were performed using random- or fixed-effect models based on heterogeneity. Seven RCTs (2013–2022; n = 15–64) were included. At 6 months, combination therapy significantly reduced serum ferritin (MD = − 689.03 ng/ml; 95% CI − 1001.45 to − 376.61; P < 0.0001) and MIC (MD = − 0.22; 95% CI − 0.42 to − 0.03; P = 0.02). At 12 months, serum ferritin (MD = − 303.30; 95% CI − 513.92 to − 92.68; P = 0.005) and MIC (MD = − 0.42; 95% CI − 0.56 to − 0.28; P < 0.00001) remained significantly reduced, with no heterogeneity. Myocardial T2* improved significantly at 12 months (MD = 4.29; 95% CI 1.58 to 7.01; P = 0.002), whereas LIC and LVEF showed no significant changes at either time point. Adjunctive amlodipine combined with standard iron chelation therapy may provide additional benefits in reducing systemic and myocardial iron burden and improving cardiac T2* in patients with transfusion-dependent thalassemia. Although these findings support the potential role of amlodipine in mitigating cardiac siderosis, they should be interpreted with caution because the available evidence is based on a limited number of relatively small RCTs with clinical and methodological heterogeneity.
No takes yet. Share an insight, caveat, or question.
Hetta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: